GeneOne Life Science진원생명과학
011000 · KOSPI · ₩011000 · 진원생명과학
₩2,670 ₩0 (0.00%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | −136.0% | −65.7% | −30.4% | −19.3% | 19.2% | 22.6% |
| Operating margin | −323.0% | −191.1% | −120.5% | −120.3% | −82.3% | −71.1% |
| Net margin | −395.7% | −225.0% | −135.9% | −193.4% | −78.1% | −41.2% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −46.3% | −35.5% | −11.2% | −17.5% | +25.9% | — |
| Operating income growth | +9.3% | −2.3% | +11.0% | −20.7% | −45.7% | — |
| Net income growth | +5.6% | −6.8% | +37.6% | −104.3% | −138.6% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −127.8% | −82.0% | −49.3% | −53.1% | −19.7% | −7.8% |
| Return on assets | −45.5% | −38.3% | −32.1% | −41.6% | −16.2% | −6.4% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 248.6% | 191.5% | 76.8% | 35.4% | 22.8% | 21.4% |
| Net debt to equity | 4.6% | 1.3% | 2.6% | −0.4% | −0.6% | −6.1% |
| Current ratio | 38.3% | 36.1% | 67.4% | 151.2% | 215.9% | 386.5% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: GeneOne Life Science / 진원생명과학 / 011000 / KRX:011000
Source: KRX statistical information